Answers are grounded in this paper and cite their sources.
Recently, it has become a consensus that systemic decreases in NAD + are a critical trigger for age-associated functional decline in multiple tissues and organs. The hypothalamus, which contains several functionally distinct subregions called nuclei, functions as a high-order control center of aging in mammals. However, due to a technical difficulty, how NAD + levels change locally in each hypothalamic nucleus during aging remains uninvestigated. We were able to establish a new combinatorial methodology, using laser-captured microdissection (LCM) and high-performance liquid chromatography (HPLC), to accurately measure NAD + levels in small tissue samples. We applied this methodology to examine local NAD + changes in hypothalamic nuclei and found that NAD + levels were decreased significantly in the arcuate nucleus (ARC), ventromedial hypothalamus (VMH), and lateral hypothalamus (LH), but not in the dorsomedial hypothalamus (DMH) of 22-month-old mice, compared to those of 3-month-old mice. The administration of nicotinamide mononucleotide (NMN) significantly increased NAD + levels in all these hypothalamic nuclei. Interestingly, the administration of extracellular nicotinamide phosphoribosyltransferase-containing extracellular vesicles (eNampt-EVs) purified from young mice increased NAD + levels in the ARC and DMH. These results reveal the unique specificity of NAD + regulation in the hypothalamus during aging.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: